BRIEF-IMFINZI Plus IMJUDO Combined With lenvatinib And TACE Reduced The Risk Of Disease Progression Or Death By 30% In Embolization-Eligible Unresectable Liver Cancer In EMERALD-3 Phase Iii Trial

Astrazeneca

Astrazeneca

AZN

0.00

June 1 (Reuters) - AstraZeneca PLC AZN.L:

  • IMFINZI® (DURVALUMAB) PLUS IMJUDO® (TREMELIMUMAB-ACTL) COMBINED WITH LENVATINIB AND TACE REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 30% IN EMBOLIZATION-ELIGIBLE UNRESECTABLE LIVER CANCER IN EMERALD-3 PHASE III TRIAL

  • ASTRAZENECA - STRIDE WITH LENVA AND TACE SHOWS POSITIVE OVERALL SURVIVAL TREND VERSUS TACE ALONE

  • ASTRAZENECA - STRIDE WITH LENVA AND TACE SHOWS 13 MONTHS MEDIAN PFS VERSUS 9.8 MONTHS FOR TACE ALONE

Source text: ID:nBw9jWmFZa

Further company coverage: AZN.L


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.